๐ฐ Beigene News
Page 20 - Beigene News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Beigene. Real-time updates on events, politics, business and more.
March 11, 2022
BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) gapped down before the market opened on Friday . The stock had previously closed at $184.00, but opened at $177.01. BeiGene shares last traded at $177.20, with a volume of 1,257 shares. BGNE has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft initiated coverage […]
March 11, 2022
Tislelizumab is now approved in seven indications in China BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative
March 11, 2022
After its first commercial launch in Carvykti, Legend Biotech's CEO talked up the rising CAR-T star's cell therapy ambitions.
March 10, 2022
A 2020 law called the Holding Foreign Companies Accountable Act may be behind the sharp decline in a handful of U.S-traded Chinese stocks.
February 17, 2022
With this approval, BRUKINSA is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE:
January 14, 2022
The FDA has slapped a clinical hold on Takeda and Denali Therapeutics' phase 1-ready Alzheimer's candidate. Daiichi Sankyo is shutting down its Plexxikon R&D facility. Legend Biotech talks manufacturing learnings from Bristol Myers Squibb's CAR-T rival.
January 7, 2022
Biogen reportedly approached Samsung for a takeover deal as the beleaguered biotech and partner Eisai's Aduhelm received rejections in Europe and Japan. Novartis bought its way into TIGIT with a BeiGene deal. And more.
December 21, 2021
Novartis is partnering with BeiGene on the development of a drug that addresses TIGIT, a hot cancer immunotherapy target. The Swiss pharma giant is committing $300 million up front, and up to $700 million more upon exercising its option on BeiGene's antibody drug.
December 21, 2021
ZURICHโNovartis has signed an option, collaboration, and license agreement with BeiGene Ltd for anti-cancer therapy ociperlimab (BGB-A1217) to ...